Skip to content

Kailera Therapeutics

US · KLRA #3073 by market cap Listed 2026
11.02 -0.56 -4.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 25 in the most recent period (2026/Q3).
  • Total institutional ownership rose 1.2 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
100.55% +1.18pp
Institutions
146 +25
As of
2026/Q3 vs. prior period

Holder types

VC/PE Fund45.18%
Mutual Fund21.43%
Hedge Fund16.56%
Public Company9.66%
Government Pension Fund5.68%
Private Company1.96%
Other0.51%

Top holders as of 2026-06-30

Bain Capital, LP 20.22% · 26.26M sh
Bain Capital Life Sciences Investors, LLC 17.39% · 22.58M sh
Jiangsu Hengrui Pharmaceuticals Co.,Ltd 8.87% · 11.51M sh
RTW Investments, LP 8.30% · 10.78M sh
Canada Pension Plan Investment Board 5.63% · 7.30M sh
Atlas Venture Advisors, Inc. 3.98% · 5.17M sh
FMR 3.59% · 4.66M sh
BlackRock 3.52% · 4.57M sh
T. Rowe Price Group, Inc. 2.72% · 3.53M sh
Citadel Advisors LLC 2.50% · 3.24M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

45 filings tracked · 23 buys · 0 sells

NameRoleStake
Bain Capital, LP -- 20.22%
Bain Capital Life Sciences Investors, LLC -- 17.39%
Ronald Renaud Chief Executive Officer 0.03%
John Milligan Independent Non-Employee Chairman --
Canada Pension Plan Investment Board -- --
Christopher Hite Independent Director --
Jiangsu Hengrui Pharmaceuticals Co.,Ltd -- --
Adam Koppel Independent Director --
Martin MacKay Independent Director --
Bain Capital Investors, LLC -- --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-06 Nur Nicholson -- Other Derivative Acquisition +220,000 $16.23
2026-07-05 Kathleen Tregoning Chief Corporate Affairs Officer Other Derivative Acquisition +175,000 $23.30
2026-06-08 Ronald Renaud Chief Executive Officer Derivative Exercise and Retained +38,094 $5.25
2026-04-19 Bain Capital, LP -- Private Acquisition +8,398,438 $16.00
2026-04-19 Bain Capital, LP -- Derivative Exercise and Retained +17,857,143 --
2026-04-19 Jiangsu Hengrui Pharmaceuticals Co.,Ltd -- Derivative Exercise and Retained +11,511,852 --
2026-04-19 RTW Investments, LP -- Private Acquisition +500,000 $16.00
2026-04-19 RTW Investments, LP -- Derivative Exercise and Retained +10,276,820 --
2026-04-19 Bain Capital Life Sciences Investors, LLC -- Private Acquisition +1,562,500 $16.00
2026-04-19 Bain Capital Life Sciences Investors, LLC -- Derivative Exercise and Retained +21,020,768 --
2026-04-15 John Milligan Independent Non-Employee Chairman Other Derivative Acquisition +38,300 $16.00
2026-04-15 John Milligan Independent Non-Employee Chairman Initial Statement of Beneficial 0 --
2026-04-15 Canada Pension Plan Investment Board -- Initial Statement of Beneficial 0 --
2026-04-15 Christopher Hite Independent Director Other Derivative Acquisition +38,300 $16.00
2026-04-15 Christopher Hite Independent Director Initial Statement of Beneficial 0 --
2026-04-15 Jiangsu Hengrui Pharmaceuticals Co.,Ltd -- Initial Statement of Beneficial 0 --
2026-04-15 Ronald Renaud Chief Executive Officer Other Derivative Acquisition +600,000 $16.00
2026-04-15 Ronald Renaud Chief Executive Officer Initial Statement of Beneficial 0 --
2026-04-15 Adam Koppel Independent Director Other Derivative Acquisition +38,300 $16.00
2026-04-15 Martin MacKay Independent Director Other Derivative Acquisition +38,300 $16.00

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Kailera Therapeutics discussion 0 comments

Add a comment